{"organizations": [], "uuid": "fd3524136e3fe4c41f0d233232aee1366efe9e1b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ra-pharma-entered-sales-agreement/brief-ra-pharma-entered-sales-agreement-with-stifel-pursuant-to-which-co-may-sell-up-to-50-mln-of-shares-of-common-stock-idUSFWN1SG1N0", "country": "US", "domain_rank": 408, "title": "BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T00:49:00.000+03:00", "replies_count": 0, "uuid": "fd3524136e3fe4c41f0d233232aee1366efe9e1b"}, "author": "", "url": "https://www.reuters.com/article/brief-ra-pharma-entered-sales-agreement/brief-ra-pharma-entered-sales-agreement-with-stifel-pursuant-to-which-co-may-sell-up-to-50-mln-of-shares-of-common-stock-idUSFWN1SG1N0", "ord_in_thread": 0, "title": "BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "stifel pursuant to which co", "sentiment": "negative"}, {"name": "brief-ra pharma", "sentiment": "negative"}, {"name": "stifel", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ra pharmaceuticals inc", "sentiment": "none"}, {"name": "shares of common stock reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Ra Pharmaceuticals Inc:\n* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: ( bit.ly/2G0vejI ) Further company coverage:\n ", "external_links": ["https://bit.ly/2G0vejI"], "published": "2018-05-10T00:49:00.000+03:00", "crawled": "2018-05-10T01:04:47.049+03:00", "highlightTitle": ""}